| Baseline Characteristics |
Total (n=314) |
ETN (n=156) |
IFX (n=32) |
ETN VS. IFX P-Value |
ADA (n=126) |
ETN VS. ADA P-value |
|---|---|---|---|---|---|---|
| Age (years), mean (SD) | 56.3 (12.6) | 55.5 (12.1) | 59.4 (14.8) | 0.111 | 56.6 (12.6) | 0.458 |
| Min, median, max | 21.0, 56.0, 90.0 | 21.0, 54.5, 84.0 | 24.0, 59.5, 82.0 | 25.0, 56.5, 90.0 | ||
| Female, n (%) | 241 (76.8) | 122 (78.2) | 26 (81.3) | 0.816 | 93 (73.8) | 0.402 |
| RA duration (years), mean (SD) | 9.0 (4.9) | 9.3 (4.7) | 8.1 (2.6) | 0.124 | 8.9 (5.5) | 0.615 |
| Quan-Charlson comorbidity score1, mean (SD) | 0.1 (0.5) | 0.1 (0.5) | 0.2 (0.6) | 0.344 | 0.1 (0.5) | 0.870 |
| Prior 3-month DMARD use, n (%) | ||||||
| None | 79 (25.2) | 47 (30.1) | 8 (25.0) | 0.672 | 24 (19.1) | 0.039 |
| One | 95 (30.3) | 46 (29.5) | 14 (43.8) | 0.145 | 35 (27.8) | 0.792 |
| More than one | 140 (44.6) | 63 (40.4) | 10 (31.3) | 0.427 | 67 (53.2) | 0.041 |
| Initiation of anti-TNF, n (%) | ||||||
| Monotherapy | 72 (22.9) | 43 (27.6) | 8 (25.0) | 0.831 | 21 (16.7) | 0.033 |
| Concomitant DMARD | 242 (77.1) | 113 (72.4) | 24 (75.0) | 0.831 | 105 (83.3) | 0.033 |
| Medication insurance, n (%) | ||||||
| Government | 159 (50.6) | 78 (50.0) | 15 (46.9) | 0.847 | 66 (52.4) | 0.720 |
| Private | 125 (39.8) | 60 (38.5) | 15 (46.9) | 0.430 | 50 (39.7) | 0.902 |
| None | 12 (3.8) | 8 (5.1) | 1 (3.1) | 1.000 | 3 (2.4) | 0.356 |
| Not government, but unknown if private or none | 4 (1.3) | 1 (0.6) | 0 (0.00) | 1.000 | 3 (2.4) | 0.328 |
| Unknown | 14 (4.5) | 9 (5.8) | 1 (3.1) | 1.000 | 4 (3.2) | 0.396 |